{"success":true,"data":{"pressRelease":{"id":"25982","rtpr_id":"nPn1BB1CXa","ticker":"ORIC","exchange":"NASDAQ","all_tickers":["ORIC"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC","author":"PR Newswire","published_at":"2026-05-07T14:00:09.813Z","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC\n\nPR Newswire\n\nNEW YORK, May 7, 2026\n\nNEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on\nbehalf of investors of ORIC Pharmaceuticals, Inc.  (\"Oric\" or the \"Company\")\n(NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com (mailto:newaction@pomlaw.com)  or 646-581-9980, ext.\n7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether Oric and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=3291928519&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DORIC&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 31, 2026, Oric issued a press release \"announced a rinzimetostat\n(ORIC-944) program update\" indicating that its prostate cancer treatment is\nroughly as effective as a competitor in the same class – falling short of\nexpectations that the drug would be the best in its class of PRC2 blockers.\n\nOn this news, Oric's stock price fell $5.20 per share, or 41%, to close at\n$7.48 per share on April 1, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=1420706742&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=%C2%A0)\nwww.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=22722681&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oric-pharmaceuticals-inc--oric-302765210.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oric-pharmaceuticals-inc--oric-302765210.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1BB1CXa","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC","author":"PR Newswire","ticker":"ORIC","created":"2026-05-07T14:00:09.813Z","tickers":["ORIC"],"exchange":"NASDAQ","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC\n\nPR Newswire\n\nNEW YORK, May 7, 2026\n\nNEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on\nbehalf of investors of ORIC Pharmaceuticals, Inc.  (\"Oric\" or the \"Company\")\n(NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com (mailto:newaction@pomlaw.com)  or 646-581-9980, ext.\n7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether Oric and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=3291928519&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DORIC&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 31, 2026, Oric issued a press release \"announced a rinzimetostat\n(ORIC-944) program update\" indicating that its prostate cancer treatment is\nroughly as effective as a competitor in the same class – falling short of\nexpectations that the drug would be the best in its class of PRC2 blockers.\n\nOn this news, Oric's stock price fell $5.20 per share, or 41%, to close at\n$7.48 per share on April 1, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=1420706742&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=%C2%A0)\nwww.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682867-4&h=22722681&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oric-pharmaceuticals-inc--oric-302765210.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oric-pharmaceuticals-inc--oric-302765210.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-07T14:00:09.851147002Z","server_sent_at_ms":1778162409851},"received_at":"2026-05-07T14:00:09.953Z","source_url":"https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-oric-pharmaceuticals-inc--oric-302765210.html"},"analysis":{"id":"20338","press_release_id":"25982","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP announced it is investigating claims on behalf of investors of ORIC Pharmaceuticals regarding potential securities fraud.\n\nThe investigation follows a March 31, 2026 program update for rinzimetostat (ORIC-944), which reportedly failed to meet best-in-class expectations and triggered a 41% stock decline.\n\nThis release is a solicitation for affected shareholders to contact the firm and does not constitute a new disclosure from the company.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc.","namedEntities":{"people":[{"name":"Danielle Peyton"}],"products":["rinzimetostat","ORIC-944"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"target"}],"dollarAmounts":[{"amount":"$5.20","context":"stock price drop on April 1, 2026"},{"amount":"$7.48","context":"closing price on April 1, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. No new disclosure from the issuer; no certified class, no settlement. Routine investigation announcement regarding prior corporate events."},"tickerRelevance":{"others":[],"primary":"ORIC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP announced it is investigating claims on behalf of investors of ORIC Pharmaceuticals regarding potential securities fraud.\n\nThe investigation follows a March 31, 2026 program update for rinzimetostat (ORIC-944), which reportedly failed to meet best-in-class expectations and triggered a 41% stock decline.\n\nThis release is a solicitation for affected shareholders to contact the firm and does not constitute a new disclosure from the company.","key_figures":null,"named_entities":{"people":[{"name":"Danielle Peyton"}],"products":["rinzimetostat","ORIC-944"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"target"}],"dollarAmounts":[{"amount":"$5.20","context":"stock price drop on April 1, 2026"},{"amount":"$7.48","context":"closing price on April 1, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:f66160e0fe5301b2","schema_hash":"sha256:12363694422af5d9","created_at":"2026-05-07T23:48:48.364Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":54676,"modelName":"glm-4.7"}}